Immunogenic cell death (ICD) converts dying cancer cells into a therapeutic vaccine and
stimulates antitumor immune responses. Here we unravel the results of an unbiased screen …

The Practice Guidelines Committee of the American Society of Blood or Marrow Transplantation
(ASBMT) sought to develop an evidence-based review about personalizing busulfan-…

Gut microbiota composition influences the clinical benefit of immune checkpoints in patients
with advanced cancer but mechanisms underlying this relationship remain unclear. …

Somatic gain-of-function mutations in isocitrate dehydrogenases (IDH) 1 and 2 are found in
multiple hematologic and solid tumors, leading to accumulation of the oncometabolite (R)-2-…

Most of oral targeted therapies are tyrosine kinase inhibitors (TKIs). Oral administration
generates a complex step in the pharmacokinetics (PK) of these drugs. Inter-individual PK …

Most anticancer drugs are characterised by a steep dose–response relationship and narrow
therapeutic window. Inter-individual pharmacokinetic (PK) variability is often substantial. …

We present three pediatric patients with BRAFV600E mutant high‐grade gliomas treated by
vemurafenib on a nominative authorization level at our institution. One patient with …

Objectives: Vandetanib was approved by the US Food and Drug Association for the treatment
of advanced medullary thyroid cancer (MTC). Because body weight (BW) loss is observed …

Therapeutic drug monitoring (TDM) can be defined as the measurement of drug in biological
samples to individualise treatment by adapting drug dose to improve efficacy and/or reduce …

Oncogenic isocitrate dehydrogenase (IDH)1 and IDH2 mutations at three hotspot arginine
residues cause an enzymatic gain of function that leads to the production and accumulation of …